{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(2)"],"submitter":["Dohna M"],"pubmed_abstract":["Purpose To assess the feasibility of monitoring the effects of elexacaftor-tezacaftor-ivacaftor (ETI) therapy on lung ventilation and perfusion in people with cystic fibrosis (CF), using phase-resolved functional lung (PREFUL) MRI. Materials and Methods This secondary analysis of a multicenter prospective study was carried out between August 2020 and March 2021 and included participants 12 years or older with CF who underwent PREFUL MRI, spirometry, sweat chloride test, and lung clearance index assessment before and 8-16 weeks after ETI therapy. For PREFUL-derived ventilation and perfusion parameter extraction, two-dimensional coronal dynamic gradient-echo MR images were evaluated with an automated quantitative pipeline. T1- and T2-weighted MR images and PREFUL perfusion maps were visually"],"journal":["Radiology. Cardiothoracic imaging"],"pagination":["e230104"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11056757"],"repository":["biostudies-literature"],"pubmed_title":["PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study."],"pmcid":["PMC11056757"],"pubmed_authors":["Wacker F","Vogel-Claussen J","Dohna M","Pallenberg ST","Hansen G","Renz DM","Dittrich AM","Glandorf J","Voskrebenzev A","Kaireit TF","Klimes F","Ringshausen FC"],"additional_accession":[]},"is_claimable":false,"name":"PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study.","description":"Purpose To assess the feasibility of monitoring the effects of elexacaftor-tezacaftor-ivacaftor (ETI) therapy on lung ventilation and perfusion in people with cystic fibrosis (CF), using phase-resolved functional lung (PREFUL) MRI. Materials and Methods This secondary analysis of a multicenter prospective study was carried out between August 2020 and March 2021 and included participants 12 years or older with CF who underwent PREFUL MRI, spirometry, sweat chloride test, and lung clearance index assessment before and 8-16 weeks after ETI therapy. For PREFUL-derived ventilation and perfusion parameter extraction, two-dimensional coronal dynamic gradient-echo MR images were evaluated with an automated quantitative pipeline. T1- and T2-weighted MR images and PREFUL perfusion maps were visually","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-10T03:21:08.565Z","creation":"2026-06-10T03:12:54.504Z"},"accession":"S-EPMC11056757","cross_references":{"pubmed":["38573129"],"doi":["10.1148/ryct.230104"]}}